<unk>  is a kinase inhibitor that is FDA approved for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.   Common adverse reactions include diarrhea, photosensitivity reaction, nausea, pyrexia, and vomiting (≥20%).
Cobimetinib
Binimetinib
Trametinib
Lestaurtinib
Stibine
Nilotinib
Gefitinib
Erlotinib